(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the submission of a New Drug Application to the FDA for olanzapine extended-release injectable suspension for the treatment of schizophrenia in adults. The NDA for olanzapine Olanzapine long-acting injectable is based on results from the Phase 3 SOLARIS trial. Olanzapine long-acting injectable utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine.
"The innovation of olanzapine LAI comes from its delivery of olanzapine, a foundational treatment for schizophrenia, as a once-monthly subcutaneous formulation, said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
